Latham & Watkins advises eFFECTOR Therapeutics in US$7.5 million registered direct offering. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...
You must be a Standard 1 Year member to access this content.
Cooley advised Reneo, and Latham & Watkins advised the underwriters and placement agents. Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...
You must be a Standard 1 Year member to access this content.
